Intermediate- and high-risk melanoma

By Agarwala Sanjiv  

Current Treatment Options in Oncology, Vol. 3, Iss. 3, 2002-06 ,pp. : 205-217

Springer Publishing Company

Access to resources Recommend Favorite

Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

By Brandberg Yvonne   Johansson Hemming   Aamdal Steinar   Bastholt Lars   Hernberg Michaela   Stierner Ulrika   von der Maase Hans   Hansson Johan    

Acta Oncologica, Vol. 52, Iss. 6, 2013-08 ,pp. : 1086-1093

Informa Healthcare

Access to resources Recommend Favorite

Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial

By Stadler Rudolf   Luger Thomas   Bieber Thomas   Köhler Ulrike   Linse Ruthild   Technau Kristin   Schubert Roland   Schroth Katja   Vakilzadeh Feredoun   Volkenandt Matthias   Gollnick Harald   Von Eick Harald   Thoren Fredrik   Strannegård Örjan  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 389-399

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain

By Gonzalez-Larriba J.L.   Serrano S.   Alvarez-Mon M.   Camacho F.   Casado M.A.   Daz-Perez J.L.   Daz-Rubio E.   Fosbrook L.   Guillem V.   Lopez-Lopez J.J.   Moreno-Nogueira J.A.   Toribio J.  

European Journal of Cancer, Vol. 36, Iss. 18, 2000-12 ,pp. : 2344-2352

Elsevier

Access to resources Recommend Favorite

A Retrospective Cost-effectiveness Analysis of Interferon as Adjuvant Therapy in High-risk Resected Cutaneous Melanoma

By Messori A.   Becagli P.   Trippoli S.   Tendi E.  

European Journal of Cancer, Vol. 33, Iss. 9, 1997-08 ,pp. : 1373-1379

Elsevier

Access to resources Recommend Favorite